Latham & Watkins LLP represented Hercules in the transaction. Tricida, Inc. (Nasdaq: TCDA) has entered into a debt facility with Hercules Capital, Inc. (NYSE: HTGC), a...
Tricida’s $125 Million Debt Facility
Alphatec Spine’s $50 Million Revolving Credit Facility
Latham & Watkins represented Alphatec in the transaction. Alphatec Holdings, Inc. (Alphatec) announced the close of an asset-based revolving credit facility in the maximum aggregate amount...
Spectrum Pharmaceuticals’ $65 Million Debt Financing Agreement With SLR Capital Partners
Latham & Watkins represented Spectrum Pharmaceuticals in the deal. Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, has entered into...
Alignment Healthcare’ $250 Million Debt Financing
Latham & Watkins represented Alignment Healthcare in the transaction. Alignment Healthcare, Inc.(Alignment Healthcare) (NASDAQ: ALHC), a leading tech-enabled MedicareAdvantage company, has announced the close of an...
Marti’s Merger with Galata Acquisition Corp.
Latham & Watkins and Conyers represented Marti Technologies Inc. in the transaction. Willkie Farr & Gallagher represented Galata. White & Case represented B. Riley Securities. Galata Acquisition...
Rhythm Pharmaceuticals’ $100 Million Revenue Interest Financing Agreement With HealthCare Royalty Partners
Latham & Watkins represented Rhythm Pharmaceuticals, Inc. in the transaction, while Morgan, Lewis & Bockius acted as legal advisor to HealthCare Royalty. Rhythm Pharmaceuticals, Inc. (Nasdaq:...
SatixFy’s $813 Million Combination With Endurance Acquisition
Davis Polk and Gross & Co. advised SatixFy Communications Ltd. on the deal. Appleby and Morrison & Foerster acted for Endurance Acquisition Corp. Latham & Watkins...
Arcutis Biotherapeutics’ $225 Million Non-Dilutive Debt Financing
Latham & Watkins represented Arcutis in the transaction. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing novel innovations in immuno-dermatology, has announced that...
Mesoblast’s $90 Million Refinancing and Expansion of Senior Debt Facility
Latham & Watkins represented Mesoblast in the transaction. Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in stem cell medicines for inflammatory diseases, has announced that it has...
BridgeBio Pharma’s $750 Million Non-Dilutive Debt Financing
Latham & Watkins represented BridgeBio in the transaction. BridgeBio Pharma (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, executed a...
Stem’s $400 Million Green Convertible Senior Notes Offering
Latham & Watkins represented the initial purchasers in the offering. Stem, Inc. executed its US$400 million aggregate principal amount of 0.50% Green Convertible Senior Notes due 2028 in...
Vertical Aerospace’s $205 Million Funding
Latham & Watkins advised Vertical Aerospace on the deal. Vertical Aerospace Ltd. (“Vertical”), a global aerospace and technology company that is pioneering zero-emissions aviation, closed US$205...